BioNTech SE Sponsored ADR $BNTX Shares Sold by Altrinsic Global Advisors LLC

Key Points

• Altrinsic Global Advisors LLC reduced its holdings in BioNTech SE by selling 6,727 shares, now owning 620,766 shares, which represents 2.8% of its investment portfolio.
• Several institutional investors significantly increased their positions in BioNTech, including Bank of New York Mellon which raised holdings by 18,892.9%, acquiring an additional 694,691 shares.
• BioNTech's most recent earnings report showed a revenue of $306.46 million, exceeding estimates, but the company posted a loss of ($1.60) earnings per share, which missed analysts' expectations.

Altrinsic Global Advisors LLC cut its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 1.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 620,766 shares of the company's stock after selling 6,727 shares during the period. BioNTech comprises about 2.8% of Altrinsic Global Advisors LLC's investment portfolio, making the stock its 12th largest position. Altrinsic Global Advisors LLC owned 0.26% of BioNTech worth $56,527,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in BioNTech during the 4th quarter worth about $584,000. CANADA LIFE ASSURANCE Co grew its holdings in BioNTech by 63.5% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,791 shares of the company's stock worth $887,000 after acquiring an additional 3,025 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in BioNTech by 61.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock worth $214,000 after acquiring an additional 713 shares in the last quarter. T. Rowe Price Investment Management Inc. bought a new position in BioNTech during the 4th quarter worth about $6,078,000. Finally, Banco Bilbao Vizcaya Argentaria S.A. bought a new position in BioNTech during the 4th quarter worth about $786,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on BNTX shares. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Truist Financial reissued a "buy" rating and set a $155.00 price target (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. JPMorgan Chase & Co. decreased their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. Wells Fargo & Company set a $150.00 price objective on shares of BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. Finally, Leerink Partners set a $112.00 price objective on shares of BioNTech in a research report on Monday, June 2nd. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $135.80.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded down $1.93 during midday trading on Friday, reaching $100.00. 505,409 shares of the stock were exchanged, compared to its average volume of 929,146. The firm has a market cap of $24.04 billion, a price-to-earnings ratio of -62.50 and a beta of 1.23. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $131.49. The firm has a 50-day simple moving average of $109.79 and a two-hundred day simple moving average of $105.18. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The firm had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.BioNTech's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. As a group, analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.